Benitec Biopharma switches auditor to Ernst & Young from Baker Tilly
Bitget2026/09/24 20:39- Benitec Biopharma replaced auditor Baker Tilly with Ernst & Young for the fiscal year ending June 30, 2027.
- Audit committee dismissed Baker Tilly on Sept. 18, 2026; Baker Tilly was notified on Sept. 21, 2026.
- Baker Tilly’s audit opinions for fiscal 2026 and 2025 were unqualified, with no going-concern or scope modifications.
- No accounting or auditing disputes were reported with Baker Tilly through Sept. 21, 2026.
- Only reportable issue cited was a 2025 material weakness in share-based compensation controls, remediated by June 30, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Half a million miners stand between Bolivia and a critical minerals rush
US factory orders rose by 0.1% month-on-month in August; AI infrastructure supports manufacturing, but decline in aircraft orders offset part of the increase
The U.S. Census Bureau reported on Friday that factory orders in August increased by 0.1% month-on-month, in line with market expectations, and rose by 6.8% year-on-year. The July month-on-month increase was revised down from 0.9% to 0.8%. Orders for machinery and electrical equipment grew by 1.1% month-on-month, while orders for civilian aircraft and parts saw a significant decline of 4.3% month-on-month. Excluding aircraft, non-defense capital goods orders increased by 1.6% month-on-month.
ONDO falls below $0.5
Crypto prices
More
